Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Last updated date
Last updated date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (3)
Type
(
1 selected
)
Type
Guidance (815)
Guidance programme
(
2 selected
)
Guidance programme
Antimicrobial prescribing guidelines (20)
Cancer service guidelines (8)
Clinical guidelines (225)
COVID-19 rapid guidelines (3)
Diagnostics guidance (48)
Health technology evaluations (18)
Highly specialised technologies guidance (28)
Interventional procedures guidance (603)
Medical technologies guidance (67)
Medicines practice guidelines (5)
NICE guidelines (341)
Public health guidelines (61)
Safe staffing guidelines (2)
Social care guidelines (71)
Technology appraisal guidance (787)
Apply filters
Showing 1 to 10 of 815
Sort by
Date
Title
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance programme: Highly specialised technologies guidance
Remove Guidance programme: Highly specialised technologies guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Abaloparatide for treating osteoporosis after menopause
TA991
7 August 2024
7 August 2024
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)
TA568
13 March 2019
13 March 2019
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
TA373
16 December 2015
16 December 2015
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
TA563
27 February 2019
27 February 2019
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
TA810
20 July 2022
20 July 2022
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
TA725
15 September 2021
15 September 2021
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
TA259
27 June 2012
27 July 2016
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
TA387
27 April 2016
27 July 2016
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
TA721
18 August 2021
18 August 2021
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
TA814
3 August 2022
3 August 2022
Current page
1
2
3
…
82
Page
1
of
82
Next page
Results per page
10
25
50
All
Back to top